Through this study, the investigators are to prove that Cilostazol effectively prevent progression of intima-medial thickness in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects.

The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the progression of intima-medial thickness compared to aspirin in the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.

Inclusion Criteria:

• Clinical diagnosis of ischemic stroke within 120 days
• Adult aged 20 years or older
• High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage)
• Informed consent

Exclusion Criteria:

• Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks
• Bleeding tendency
• Pregnant or breast-feeding woman
• Hemorrhagic stroke within 6 months
• Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication
• Severe cardiovascular disease such as cardiomyopathy or congestive heart failure
• Life expectancy less than one year
• Contraindication to long term aspirin use
• Enrolled in other clinical trial within 30 days